Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin

C J Honsik, G Jung, R A Reisfeld, C J Honsik, G Jung, R A Reisfeld

Abstract

Monoclonal antibodies 14.18 (IgG3) and 11C64 (IgG3) directed against disialogangliosides GD2 and GD3, respectively, when used in conjunction with human peripheral blood mononuclear cells (PBMCs) stimulated with human recombinant interleukin (rIL-2) lyse both human melanoma and neuroblastoma cells by antibody-dependent cellular cytotoxicity. Such monoclonal antibody-"armed" effector cells are specifically directed to targets expressing the given disialoganglioside without detectable cross-reactivity. In addition, antibody-dependent cellular cytotoxicity as well as the natural killing ability of human PBMCs is augmented by a brief coincubation with rIL-2. PBMCs augmented by rIL-2 and armed with monoclonal antibodies significantly suppressed tumor growth in the xenotransplant nude mouse model. Our results suggest that once a threshold level of activation of PBMCs is achieved, additional rIL-2 (over three orders of magnitude of concentration) does not significantly enhance cytolytic augmentation. Furthermore, anti-GD3 monoclonal antibody 11C64 together with rIL-2-stimulated PBMCs from melanoma patients with widely differing tumor burdens effectively lyse melanoma tumor targets in antibody-dependent cellular cytotoxicity. Our results also suggest that GD2 and GD3 represent distinct and relevant immunotherapeutic target structures on melanoma whereas GD2 does the same for neuroblastoma tumors. Our data suggest that targeting of activated human effector cells may provide a new and effective cancer immunotherapy protocol.

References

    1. J Exp Med. 1983 Oct 1;158(4):1356-61
    1. J Exp Med. 1982 Jun 1;155(6):1823-41
    1. Science. 1984 Jun 29;224(4656):1431-3
    1. J Immunol. 1984 Aug;133(2):714-8
    1. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5767-71
    1. J Biol Chem. 1984 Nov 25;259(22):13674-9
    1. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242-6
    1. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1499-502
    1. Proc Natl Acad Sci U S A. 1985 Aug;82(15):5155-9
    1. N Engl J Med. 1985 Dec 5;313(23):1485-92
    1. J Exp Med. 1986 Jan 1;163(1):166-78
    1. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8653-7
    1. J Neurochem. 1963 Sep;10:613-23
    1. Immunochemistry. 1978 Jul;15(7):429-36
    1. J Immunol. 1980 Jul;125(1):238-45
    1. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6114-8
    1. Cancer Res. 1981 Nov;41(11 Pt 1):4420-5
    1. J Exp Med. 1982 Apr 1;155(4):1133-47
    1. Cancer Res. 1984 Feb;44(2):806-10

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅